company

Themis – The Vaccine Innovation Boutique

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases.

We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Themis’ core lead technology, Themaxyn™ - a highly novel, patent-protected, and innovative vaccine platform which originates from a world-leading European vaccine research institute - will be used to create novel vaccines. The Company’s first vaccine targets are emerging tropical and travelers diseases, including dengue, chikungunya and yellow fever virus, and there is clear potential to expand the Themaxyn™ technology to further indications.

Themis was founded in September 2009 and is based in Vienna. The founders and management team Dr. Erich Tauber, Dr. André Habel and Mag. Katharina Wieser are experienced vaccine experts with successful, established track records in the biotechnology industry and have worked alongside each other for a number of years.